The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients
Open accessAbstract
Objective: Several randomized, placebo‐controlled, double‐blind trials in insulin‐treated patients with type 2 diabetes have shown that adjunctive therapy with pramlintide reduces hemoglobin (Hb)A 1c with concomitant weight loss. This analysis further characterizes the weight‐lowering effect of pramlintide in this patient population. Research Methods and Procedures: This pooled post hoc analysis of two long‐term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m 2), and who were treated with either 120 μg pramlintide BID (n = 254; HbA 1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA 1c 9.4%; weight, 95.0 kg). Statistical endpoints included changes from baseline to week 26 in HbA 1c, body weight, and insulin use. Results: Pramlintide treatment resulted in significant reductions from baseline to week 26, compared with placebo, in HbA 1c and body weight (both, p < 0.0001), for placebo‐corrected reductions of −0.41% and −1.8 kg, respectively. Approximately three times the number of patients using pramlintide experienced a ≥5% reduction of body weight than with placebo (9% vs. 3%, p = 0.0005). Patients using pramlintide also experienced a proportionate decrease in total daily insulin use (r = 0.39, p < 0.0001). The greatest placebo‐corrected reductions in weight at week 26 were observed in pramlintide‐treated patients with a BMI >40 kg/m 2 and in those concomitantly treated with metformin (both, p < 0.001), for placebo‐corrected reductions of −3.2 kg and −2.5 kg, respectively. Discussion: These findings support further evaluation of the weight‐lowering potential of pramlintide in obese patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Self-citationHollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Self-citationHenry, R. R., Gumbiner, B., Ditzler, T., Wallace, P., Lyon, R., & Glauber, H. S. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.21 · Cited by 227
Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156
Self-citationEffects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112
Cited by
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Akbari, P., Gilani, A., Sosina, O., Kosmicki, J. A., Khrimian, L., Fang, Y.-Y., Persaud, T., Garcia, V., Sun, D., Li, A., et al. (2021) · Science · doi:10.1126/science.abf8683 · Cited by 276
Metadata
- Authors
- Hollander, P., Maggs, D. G., Ruggles, J. A., Fineman, M., Shen, L., Kolterman, O. G., & Weyer, C.
- Venue
- Obesity Research
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 12
- Issue
- 4
- Pages
- 661-668
- ISSN
- 1071-7323 (ISSN-L)
- 1550-8528
- OpenAlex
- W2047864863
- Cited by
- 191
- References
- 5
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.